Cargando…
Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report
BACKGROUND: Renal clear cell carcinoma (RCC) is a malignant tumor of the genitourinary system with a predilection for males. The most common metastatic sites are the lung, liver, lymph nodes, contralateral kidney or adrenal gland, however, skin metastasis has only been seen in 1.0%-3.3% of cases. Th...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044962/ https://www.ncbi.nlm.nih.gov/pubmed/36998957 http://dx.doi.org/10.12998/wjcc.v11.i9.2104 |
_version_ | 1784913477309038592 |
---|---|
author | Dong, Shuai Xu, Yang-Chun Zhang, Yuan-Chen Xia, Jian-Xin Mou, Yan |
author_facet | Dong, Shuai Xu, Yang-Chun Zhang, Yuan-Chen Xia, Jian-Xin Mou, Yan |
author_sort | Dong, Shuai |
collection | PubMed |
description | BACKGROUND: Renal clear cell carcinoma (RCC) is a malignant tumor of the genitourinary system with a predilection for males. The most common metastatic sites are the lung, liver, lymph nodes, contralateral kidney or adrenal gland, however, skin metastasis has only been seen in 1.0%-3.3% of cases. The most common site of skin metastasis is the scalp, and metastasis to the nasal ala region is rare. CASE SUMMARY: A 55-year-old man with clear cell carcinoma of the left kidney was treated with pembrolizumab and axitinib for half a year after surgery and was found to have a red mass on his right nasal ala for 3 mo. The skin lesion of the patient grew rapidly to the size of 2.0 cm × 2.0 cm × 1.2 cm after discontinuation of targeted drug therapy due to the coronavirus disease 2019 epidemic. The patient was finally diagnosed with skin metastasis of RCC in our hospital. The patient refused to undergo surgical resection and the tumor shrank rapidly after resuming target therapy for 2 wk. CONCLUSION: It is rare for an RCC to metastasize to the skin of the nasal ala region. The tumor size change of this patient before and after treatment with targeted drugs shows the effectiveness of combination therapy for skin metastasis. |
format | Online Article Text |
id | pubmed-10044962 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-100449622023-03-29 Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report Dong, Shuai Xu, Yang-Chun Zhang, Yuan-Chen Xia, Jian-Xin Mou, Yan World J Clin Cases Case Report BACKGROUND: Renal clear cell carcinoma (RCC) is a malignant tumor of the genitourinary system with a predilection for males. The most common metastatic sites are the lung, liver, lymph nodes, contralateral kidney or adrenal gland, however, skin metastasis has only been seen in 1.0%-3.3% of cases. The most common site of skin metastasis is the scalp, and metastasis to the nasal ala region is rare. CASE SUMMARY: A 55-year-old man with clear cell carcinoma of the left kidney was treated with pembrolizumab and axitinib for half a year after surgery and was found to have a red mass on his right nasal ala for 3 mo. The skin lesion of the patient grew rapidly to the size of 2.0 cm × 2.0 cm × 1.2 cm after discontinuation of targeted drug therapy due to the coronavirus disease 2019 epidemic. The patient was finally diagnosed with skin metastasis of RCC in our hospital. The patient refused to undergo surgical resection and the tumor shrank rapidly after resuming target therapy for 2 wk. CONCLUSION: It is rare for an RCC to metastasize to the skin of the nasal ala region. The tumor size change of this patient before and after treatment with targeted drugs shows the effectiveness of combination therapy for skin metastasis. Baishideng Publishing Group Inc 2023-03-26 2023-03-26 /pmc/articles/PMC10044962/ /pubmed/36998957 http://dx.doi.org/10.12998/wjcc.v11.i9.2104 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Case Report Dong, Shuai Xu, Yang-Chun Zhang, Yuan-Chen Xia, Jian-Xin Mou, Yan Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report |
title | Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report |
title_full | Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report |
title_fullStr | Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report |
title_full_unstemmed | Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report |
title_short | Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report |
title_sort | pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044962/ https://www.ncbi.nlm.nih.gov/pubmed/36998957 http://dx.doi.org/10.12998/wjcc.v11.i9.2104 |
work_keys_str_mv | AT dongshuai pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport AT xuyangchun pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport AT zhangyuanchen pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport AT xiajianxin pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport AT mouyan pembrolizumabcombinedwithaxitinibinthetreatmentofskinmetastasisofrenalclearcellcarcinomatonasalalaacasereport |